Latest Health News

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Sovereign Metals has delivered an Optimised Prefeasibility Study reaffirming Kasiya’s status as a globally significant rutile and graphite project, alongside advancing rehabilitation efforts and positive graphite test results.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Top End Energy Limited reported a net cash outflow in its December quarter, reducing its cash reserves to $2.76 million and leaving funding for just over two and a half quarters. The company’s cash flow dynamics highlight the ongoing financial pressures typical in early-stage oil and gas exploration.

Galileo Mining Ltd’s latest quarterly cash flow report reveals a $706,000 net cash decrease amid ongoing exploration spending, while maintaining a strong cash position of $11.3 million.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.